In last trading session, Travere Therapeutics Inc (NASDAQ:TVTX) saw 1.02 million shares changing hands with its beta currently measuring 0.74. Company’s recent per share price level of $18.25 trading at $0.2 or 1.11% at ring of the bell on the day assigns it a market valuation of $1.40B. That closing price of TVTX’s stock is at a discount of -1.92% from its 52-week high price of $18.60 and is indicating a premium of 71.95% from its 52-week low price of $5.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.84 million shares which gives us an average trading volume of 1.74 million if we extend that period to 3-months.
For Travere Therapeutics Inc (TVTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.44. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Upright in the green during last session for gaining 1.11%, in the last five days TVTX remained trading in the green while hitting it’s week-highest on Thursday, 10/17/24 when the stock touched $18.25 price level, adding 3.03% to its value on the day. Travere Therapeutics Inc’s shares saw a change of 103.00% in year-to-date performance and have moved 6.66% in past 5-day. Travere Therapeutics Inc (NASDAQ:TVTX) showed a performance of 27.18% in past 30-days. Number of shares sold short was 6.96 million shares which calculate 2.9 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 21.5 to the stock, which implies a rise of 15.12% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would jump 34.25% in reaching the projected high whereas dropping to the targeted low would mean a gain of 34.25% for stock’s current value.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Statistics highlight that Travere Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 214.66% of value to its shares in past 6 months, showing an annual growth rate of 22.09% while that of industry is 17.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.34% during past 5 years.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
BLACKROCK INC. is the top institutional holder at TVTX for having 7.64 million shares of worth $62.84 million. And as of 2024-06-30, it was holding 9.8642 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 7.5 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6774 of outstanding shares, having a total worth of $61.65 million.
